About this Research Topic
The field of endocrine-related cancers is rapidly evolving, driven by significant advancements in understanding the molecular and genetic underpinnings of these diseases. These cancers, which include various malignancies affecting the endocrine system, pose unique challenges due to their complex interactions with hormonal pathways. The development of targeted therapies has skyrocketed in recent years, bringing hope for more effective and personalized treatment options. Concurrently, the discovery and validation of biomarkers have become pivotal in diagnosis, prognostication, and guidance on therapy decision-making, marking a shift towards precision oncology. Additionally, innovative research methodologies, such as organoid and organ-on-a-chip technologies, have emerged and provided more accurate models of tumor biology and drug response. These advancements underscore the importance of translational medicine in bridging the gap between laboratory research and clinical application, offering new avenues for understanding and combating endocrine-related cancers. This dynamic landscape calls for a comprehensive exploration of current trends and future directions in the research and treatment of these complex malignancies.
The primary goal of this Research Topic is to catalyze groundbreaking research and foster a deeper understanding of endocrine-related cancers. By highlighting innovative studies in targeted therapies, biomarker research, and advanced modeling techniques like organoids and organ-on-a-chip, we aim to bridge the gap between experimental research and clinical practice. Our objective is to create a collaborative platform that not only disseminates cutting-edge scientific knowledge but also encourages the development of novel therapeutic strategies, ultimately contributing to improved patient outcomes in the realm of endocrine-related oncology.
We warmly invite researchers worldwide to share their original research and innovative insights, collectively advancing the scientific development in this field. The column will cover:
• Innovations in Targeted Therapy: Studies on new targeted therapies, including their mechanisms of action and clinical applications in endocrine-related cancers. Discussions on resistance to current targeted treatments and strategies to overcome them are encouraged.
• Discovery and Application of Biomarkers: Submissions on the identification, validation, and application of new biomarkers in therapeutic decision-making. Analysis of the role of biomarkers in revealing the heterogeneity of endocrine-related cancers.
• Application of Organoid and Organ-on-a-Chip Technologies in Cancer Research: Contributions using organoid models and organ-on-a-chip technologies for tumor microenvironment simulation and drug response studies are welcomed. Exploration of the potential of these models in personalized medicine and new drug development.
• Opportunities and Challenges in Interdisciplinary Research: Interdisciplinary research that combines genomics, proteomics, bioinformatics, and other fields. Discussions on accelerating cancer treatment progress through interdisciplinary collaboration.
• New Perspectives in Clinical and Translational Research: Sharing of cases where laboratory research has been translated into clinical applications, including clinical trials and patient treatment outcomes. Discussions on the challenges and opportunities in translating laboratory findings into clinical practice.
The primary goal of this Research Topic is to catalyze groundbreaking research and foster a deeper understanding of endocrine-related cancers. By highlighting innovative studies in targeted therapies, biomarker research, and advanced modeling techniques like organoids and organ-on-a-chip, we aim to bridge the gap between experimental research and clinical practice. Our objective is to create a collaborative platform that not only disseminates cutting-edge scientific knowledge but also encourages the development of novel therapeutic strategies, ultimately contributing to improved patient outcomes in the realm of endocrine-related oncology.
We warmly invite researchers worldwide to share their original research and innovative insights, collectively advancing the scientific development in this field. The column will cover:
• Innovations in Targeted Therapy: Studies on new targeted therapies, including their mechanisms of action and clinical applications in endocrine-related cancers. Discussions on resistance to current targeted treatments and strategies to overcome them are encouraged.
• Discovery and Application of Biomarkers: Submissions on the identification, validation, and application of new biomarkers in therapeutic decision-making. Analysis of the role of biomarkers in revealing the heterogeneity of endocrine-related cancers.
• Application of Organoid and Organ-on-a-Chip Technologies in Cancer Research: Contributions using organoid models and organ-on-a-chip technologies for tumor microenvironment simulation and drug response studies are welcomed. Exploration of the potential of these models in personalized medicine and new drug development.
• Opportunities and Challenges in Interdisciplinary Research: Interdisciplinary research that combines genomics, proteomics, bioinformatics, and other fields. Discussions on accelerating cancer treatment progress through interdisciplinary collaboration.
• New Perspectives in Clinical and Translational Research: Sharing of cases where laboratory research has been translated into clinical applications, including clinical trials and patient treatment outcomes. Discussions on the challenges and opportunities in translating laboratory findings into clinical practice.
Keywords: Endocrine-Related Cancers, Targeted Therapies, Biomarker Research, Organoid Technology, Translational Medicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
